EMBO Molecular Medicine (Apr 2024)

CBX3 antagonizes IFNγ/STAT1/PD-L1 axis to modulate colon inflammation and CRC chemosensitivity

  • Yao Xiang,
  • Jorge Mata-Garrido,
  • Yuanji Fu,
  • Christophe Desterke,
  • Eric Batsché,
  • Ahmed Hamaï,
  • Christine Sedlik,
  • Youssouf Sereme,
  • David Skurnik,
  • Abdelali Jalil,
  • Rachel Onifarasoaniaina,
  • Eric Frapy,
  • Jean-Christophe Beche,
  • Razack Alao,
  • Eliane Piaggio,
  • Laurence Arbibe,
  • Yunhua Chang

DOI
https://doi.org/10.1038/s44321-024-00066-6
Journal volume & issue
Vol. 16, no. 6
pp. 1404 – 1426

Abstract

Read online

Abstract As an important immune stimulator and modulator, IFNγ is crucial for gut homeostasis and its dysregulation links to diverse colon pathologies, such as colitis and colorectal cancer (CRC). Here, we demonstrated that the epigenetic regulator, CBX3 (also known as HP1γ) antagonizes IFNγ signaling in the colon epithelium by transcriptionally repressing two critical IFNγ-responsive genes: STAT1 and CD274 (encoding Programmed death-ligand 1, PD-L1). Accordingly, CBX3 deletion resulted in chronic mouse colon inflammation, accompanied by upregulated STAT1 and CD274 expressions. Chromatin immunoprecipitation indicated that CBX3 tethers to STAT1 and CD274 promoters to inhibit their expression. Reversely, IFNγ significantly reduces CBX3 binding to these promoters and primes gene expression. This antagonist effect between CBX3 and IFNγ on STAT1/PD-L1 expression was also observed in CRC. Strikingly, CBX3 deletion heightened CRC cells sensitivity to IFNγ, which ultimately enhanced their chemosensitivity under IFNγ stimulation in vitro with CRC cells and in vivo with a syngeneic mouse tumor model. Overall, this work reveals that by negatively tuning IFNγ-stimulated immune genes’ transcription, CBX3 participates in modulating colon inflammatory response and CRC chemo-resistance.

Keywords